Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer

Next Previous
Trial Profile

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Giredestrant (Primary) ; Anastrozole; Exemestane; Letrozole; LHRH receptor agonists; Tamoxifen
  • Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer; Male breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms LidERA Breast Cancer
  • Sponsors Roche

Most Recent Events

  • 09 Mar 2026 According to a Genentech media release, In the coming weeks, Roche will submit the giredestrant phase III lidERA data in early-stage breast cancer to the FDA.
  • 20 Feb 2026 Protocol has been amended addition in arms.
  • 20 Feb 2026 According to a Genentech media release, In the coming weeks, company will submit the giredestrant Phase III lidERA data in early-stage breast cancer to the FDA in the coming weeks

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top